About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Pages
Pages
Home
About
Blog
Blog Post
Contact
Portfolio
Investors
Investor Single
Shop
Shop Single
Utility Pages
Start Here
Style Guide
404 Not Found
Password Protected
Licenses
Changelog
Browse More Templates
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
Article Date
February 10, 2026
This article is featured on another website.
Go to article
Related posts
Browse all articles
July 31, 2026
What Makes a Modern CRO? Inside HiRO’s Global Growth Story
Part 1 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 31, 2026
What Makes a Modern CRO? Inside HiRO’s Global Growth Story
Part 1 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
